Loading patent…
AssigneesBruker BioSpin GmbH, Murdoch University
InventorsJeremy K. NICHOLSON, Elaine HOLMES, Samantha LODGE, Julien WIST, Wolfgang BERMEL, Tony REINSPERGER, Philipp NITSCHKE
Estimating the term…
1H-NMR spectroscopic molecular markers are provided for identifying medical risk signatures such as SARS-CoV-2 infection, acute inflammation, or a cardiovascular risk condition. The markers use a combination of NMR intensity signals, including a Glyc signal from at least one N-acetyl (—NCOCH3) glycoprotein and an SPC signal from a choline head group (+N—(CH3)3) of a supramolecular phospholipids cluster (SPC) present in HDL and LDL lipoprotein subfractions. The Glyc signal is in a chemical shift region from #=2.00 ppm to #=2.20 ppm, and includes signals GlycA (2.00 ppm to 2.09 ppm) and GlycB (2.09 ppm to 2.2 ppm). The SPC signal is in a chemical shift region from #=3.20 ppm to #=3.30 ppm, and includes signals SPC1 (3.2 ppm to 3.235) ppm, SPC2 (3.235 ppm to 3.26 ppm), and SPC3 (3.26 ppm to 3.3 ppm). A system for identifying the markers is also provided.
A 1H-NMR spectroscopic molecular marker for identifying a medical risk signature in an in vitro blood plasma or serum sample from a patient by 1H NMR spectroscopy, wherein the marker comprises a combination of NMR intensity signals having magnitudes that are significantly different from known corresponding NMR intensity levels for a healthy patient, including a Glyc signal from at least one N-acetyl (—NCOCH3) glycoprotein and an SPC signal from a choline head group (+N—(CH3)3) of a supramolecular phospholipids cluster (SPC) present in HDL and LDL lipoprotein subfractions.
A method of diagnosing a medical risk signature in a patient, the method comprising:
A system for identifying a medical risk signature using an in vitro blood plasma or serum sample from a patient, the system comprising:
Dependencies are inferred from the claim text.